A 2 year and 8 month old CMV-negative boy suffering from stage III neuroblastoma underwent ABMT in first very good partial remission. He acquired early CMV infection on day +5, followed by consecutive graft failure and severe sepsis, and the clincial course deteriorated. Between days +16 and +21, he received seven leukocyte concentrates (LC) collected from a healthy, but CMV-IgG-seropositive relative stimulated with G-CSF (filgastrim, 5 g/kg/day). 
Life-threatening infections are still the most severe transplant-related complications in the immunocompromised host. Recently, new strategies have been developed to treat severe sepsis in these patients. In bacterial and fungal infections, leukocyte concentrates (LCs) have been used that were collected from healthy donors stimulated with G-CSF. 1 In viral infections with adenovirus 2 or CMV, 3 or in EBV-associated lymphoproliferative disease, 4 donor lymphocytes have been transfused to improve the survival of these patients. While the latter therapy employs nonirradiated cells obtained from the original allogeneic bone marrow donor to allow the generation of an immunological response to certain antigens, 5 leukocyte transfusion therapy is performed after irradiation of cells usually collected from relatives. In cases of life-threatening viral infections arising after autologous bone marrow transplantation (ABMT), however, the patient can not be treated with viable allo-geneic lymphocytes. The only alternative for these patients seems to be the rapid reconstitution of their own immune system to reduce the complications associated with opportunistic infections as recently described for CMV. 6 We provide evidence that irradiated LCs from a healthy, but CMV-seropositive donor had a curative effect on a lifethreatening viral infection acquired after unsuccessful ABMT. The patient recovered from the infection and showed normal hematopoietic reconstitution after infusion of his rescue bone marrow.
Materials and methods
Leukocyte collection and transfusion were carried out according to the local protocol approved by an ethics committee. Inclusion criteria comprised Ͻ200 granulocytes/l blood, expected aplasia for more than 3 days, clinical signs of severe sepsis, and insufficient clinical response to empirical antibacterial, antifungal and antiviral therapy within 48 h. After written informed consent, the donor was stimulated with G-CSF (filgrastim, Amgen, Thousand Oaks, CA, USA 5 g/kg/day). Eight hours later, continuous flow cell collection via peripheral venous access was performed on a Spectra (Cobe, BCT, Lakewood, CO, USA) in the local transfusion center. LCs were irradiated with 30 Gy and infused immediately.
Flow cytometric analyses to quantify all leukocyte subtypes were performed regularly from the patient's peripheral blood, as well as from three of the seven LCs. Twoand three-color combinations of monoclonal antibodies (Mabs) were employed as FITC, R-PE and R-PE-Cy5 conjugates. They were CD3 (UCHT1), CD8 (DK25), CD14 (TÜ K4), CD15 (C3D-1), CD45 (T29/33), (all from Dakopatts, Glostrup, Denmark), and CD4 (SK3), CD56 (NCAM16.2), CD33 (P76.6), (all from Becton Dickinson, Sunnyvale, CA, USA). Cell preparation and immunological staining were done as described elsewhere. 7 A FACSCalibur (Becton Dickinson) equipped with the CELLQUEST and the PAINT-A-GATE PRO softwares (Becton Dickinson) was used for data acquisition and analysis. After six high-dose chemotherapies, he was in good partial remission. At first surgery, the tumor could not be totally resected. Another course of high-dose cyclophosphamide was followed by second-look surgery. Thereafter, tumor tissue was seen by CT scan and by ultrasound, in lymph nodes near the truncus coeliacus. Due to these circumstances, ABMT was scheduled following irradiation of the tumor bed. The boy was seronegative for CMV at day −11 before ABMT although he had been seropositive (IgG-posi + cells/kg. On day +5, he developed a capillary leak syndrome and presented with oliguria, general edema and circulatory instability, in addition to mucositis (WHO grade IV) and epidermolysis (WHO grade IV). He was treated according to the local supportive care program for bone marrow transplantation which includes a laminar air flow room, oral decontamination, enteral feeding by nasogastric tube, the use of CMV-negative blood products, use of G-CSF (5 g/kg daily from day +5) and Pneumocystis carinii pneumonia prophylaxis.
On day +1, PCR analysis revealed CMV positivity in the sputum, followed by the peripheral blood on day +6 (Table 1) . Whether this was due to a reactivation of an earlier infection or whether it represented a new infection transmitted by blood products remains unclear. Ganciclovir was administered from day +3 (10 mg/kg/day for 9 days and 5 mg/kg/day until day +32). In addition, CMV hyperimmune globulin (1 ml/kg) was given twice weekly between days +4 and +33. Antibiotic treatment commenced on day zero and was extended to amphotericin B and fluconazol on day +9 when CRP values increased to 29.6 mg/dl (normal value Ͻ1 mg/dl), and when cultures from skin and mucosa became positive for Candida albicans. Blood cultures remained negative for fungal and bacterial agents. The patient developed hepatosplenomegaly, chest X-ray showed lung infiltrates, and he became dependent on oxygen. Following a focal motor seizure, he was admitted to the pediatric intensive care unit on day +11. CT scan of the brain was normal and the cerebral fluid was negative for encephalitis or an infectious agent. Despite G-CSF support, he showed no signs of hematopoietic reconstitution by day +15.
Due to the life-threatening infection, to the continuous clinical deterioration, and to an expected prolonged aplasia, we decided to treat the patient with leukocyte concentrates from his healthy father stimulated with rh-G-CSF. Initial examination of the donor blood showed normal blood values except for an IgG-positive, but IgM-and PCR-negative CMV status. Between days +16 and +21, the patient received seven LCs from the same donor, who did not report any severe side-effects. LCs contained a median of 75% PMN (range 37-85) and of 25% lymphocytes (range 9-40). The patient received daily doses of 5.7 × 10 10 PMN (range 1
9 PMN (range 0.5-3.5) and 0.56 × 10 9 lymphocytes (range 0.26-1.3) per kg. His WBC count rose from 150/l on day +15 to a maximum of 3200/l on day +18. The CRP value decreased to 8.9 mg/dl. PCR analysis of the peripheral blood remained positive for CMV until day +13. It became first negative on day +22 and remained negative thereafter.
The patient's condition improved rapidly during the period of leukocyte transfusions. Adverse therapy-related reactions were a few mild febrile episodes and a transient increase in lung infiltrates accompanied by pleural effusions, but there was no increase in oxygen requirement. Following the last LC transfusion on day +21, his WBC count decreased to 400/l, and the CRP increased to 12 mg/dl by day +23. At this time, the patient received his rescue bone marrow (2.7 × 10 6 CD34 + cells/kg). After complete aplasia on day +27 (day +4 after second ABMT), he engrafted on day +41/+18 with a WBC count consistently above 1000/l. Platelet and erythrocyte transfusions were required until he was discharged from the hospital on day +67/+42. One year after ABMT, he is still in complete remission and in a very good clinical state.
Regular flow cytometric analyses were carried out to quantify the different leukocyte populations in the patient's blood and in the LCs. The number of CD3 + peripheral T cells increased during the course of leukocyte transfusions, from 9/l after infusion of the first LC, to a maximum of 209/l after the sixth LC (Table 2) . T lymphocytes persisted after discontinuation of the transfusion therapy. They decreased after the second ABMT and reached 450/l after 28 days. The same was true for the CD4 + and CD8 + T cell subsets and for the NK cells and cytotoxic T cells ( Table  2 ). The results of the quantitative flow cytometric analyses performed on three of the seven LCs are also summarized in Table 2 . The median percentage of CD3 + T cells was almost 11% of the leukocytes infused, corresponding to Ͼ400 × 10 6 T cells per kg body weight in each of the LCs. The number of CD3 − /CD56
+ NK cells was Ͼ50 × 10 6 per LC ( Table 2) .
Discussion
We report a pediatric patient who acquired a transplantrelated life-threatening infection with CMV during the aplastic phase following ABMT. After the initial standard therapy with ganciclovir and hyperimmune globulin, there was Transfused cells are given as cells per kg of the recipient. Leukocyte subtypes were measured by FACS analyses. Blood samples were drawn a median of 5 h (range 1-12) after LC transfusion. NC = nucleated cells; PMN = polymorphonuclear leukocytes.
no significant improvement in the clinical course. The patient did not engraft and remained neutro-and lymphopenic while the clinical course deteriorated. Although CMV was the only systemic pathogen detected, an additional, unknown infectious agent complicating the severe sepsis syndrome could not be excluded. Candida albicans was considered possible, for which cultures of skin and mucosa were positive. Due to the persistent bone marrow failure and life-threatening infection, we decided to administer leukocyte concentrates from a related healthy donor, as recommended by Strauss. 8 During leukocyte transfusion therapy, both the sepsis and the related complications resolved. The CMV infection disappeared as documented by PCR analysis in which viral signals were detectable in the patient's blood until day +13, but no longer beyond day +21 (Table 1) . Due to the treatment with CMV-specific hyperimmune globulin, the patient remained IgG-seropositive but he did not acquire CMVspecific IgM antibodies suggesting that there was no active B cell immune response (Table 1) . We hypothesize that the LCs played a major role in overcoming the severe sepsis syndrome, as well as in eradicating the CMV infection, thus paving the way for the successful rescue transplantation.
It is obvious that the PMN transfused with the LCs were the cell population responsible for the patient's recovery from the severe sepsis. The number of PMN was two to three times the dosage of 2-3 × 10 10 PMNs per m 2 as recommended for adults, 1 and we maintained a PMN count of Ͼ500/l blood for 6 days ( Table 2) .
Another important cell fraction contained in the LCs were the T cells of which 3-5 ×10 8 were infused daily per kg of the recipient. There is evidence that viral infections in patients post-allogeneic BMT can be successfully treated with donor lymphocyte infusions that contain viable, nonirradiated T cells, and 1 × 10 6 T cells per kg of the recipient have been shown to be sufficient to cure EBV-associated lymphoproliferative disorders or adenoviral infections. 2, 4 In addition, CMV-specific T cell clones obtained from a seropositive donor and expanded in vitro were successfully employed to restore anti-viral immunity. 3 Four doses of 3.3 × 10 7 to 1 × 10 9 cells were infused per m 2 . While donor lymphocyte infusions may be the treatment of choice after allogeneic BMT, [2] [3] [4] [5] it is not possible to use viable, non-irradiated donor T cells after autologous transplantation. To prevent cell proliferation and a subsequent transfusion-related GVHD, the LCs were therefore irradiated with 30 Gy prior to infusion. 9 Little is known as to whether irradiated T cells can contribute in fighting viral infections. There is evidence that the effector function of irradiated T cells is preserved. T cells irradiated with doses of between 2.5 and 40 Gy were able to maintain their effector function against chlamydial pneumonia in a mouse model, 10 and IL-2 was shown to support lymphocyte survival after 15 Gy gamma irradiation in vitro, although the cells were unable to divide.
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In our case, a median of 4 × 10 8 T cells were transfused per kg/day. This was roughly 100 times the cell number given in donor lymphocyte transfusions. 2, 4 The donor was CMV seropositive, and we assume that he had CMV-specific T cell clones as shown for other CMV-seropositive donors in allogeneic BMT. 6 The peripheral T cells in our patient increased during the LC transfusions and were present for several days. After second ABMT, the WBC count dropped to 100/l. Thereafter, T cells reappeared with the beginning of autologous engraftment.
Our results suggest that the T cells contained in the LC transfusions were responsible for the first T cell peak ( Table  2 , day +20) and that they played a major role in eradicating the CMV infection.
